NICE during the pre-election period
As a public body, NICE is required to follow civil service principles on communicating during the lead up to the general election.
-
NICE International returns to deal with growing overseas enquiries
Division will offer an advisory service to international organisations, ministries and government agencies
-
Another treatment option for ovarian cancer approved for the Cancer Drugs Fund
An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE for use in the Cancer Drugs Fund (CDF).
-
NICE looks to company to ensure a new treatment for advanced breast cancer with significant unmet need is cost-effective
Draft guidance published today (3 October 2019) by NICE does not recommend atezolizumab (also called Tecentriq and made by Roche) for treating people with a type of breast cancer called triple A breast cancer that has spread to other parts of the body and who can’t have surgery to remove it.
